Abstract 5299: Monitoring of ovarian cancer recurrence and progression via Lumipulse G CA125II assay

CONCLUSION: The LUMIPULSE G CA125II assay has demonstrated to be useful in monitoring the course of disease in patients with ovarian cancer.Citation Format: Rachel R. Radwan, Savitha S. Raju, Sara J. Gannon, John Le, Sharee D. Jones, Catherine Peacock, Katherine Falcone, Julianna T. Young, Zhong-Qian Li, Diana L. Dickson. Monitoring of ovarian cancer recurrence and progression via Lumipulse G CA125II assay. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5299. doi:10.1158/1538-7445.AM2015-5299

Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Radwan, R. R., Raju, S. S., Gannon, S. J., Le, J., Jones, S. D., Peacock, C., Falcone, K., Young, J. T., Li, Z.-Q., Dickson, D. L. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research